Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) EBIT Margin (2019 - 2023)

Historic EBIT Margin for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to 249.42%.

  • ADC Therapeutics' EBIT Margin fell 2453400.0% to 249.42% in Q3 2023 from the same period last year, while for Sep 2023 it was 11.17%, marking a year-over-year increase of 448777600.0%. This contributed to the annual value of 2.36% for FY2022, which is 6163489900.0% up from last year.
  • According to the latest figures from Q3 2023, ADC Therapeutics' EBIT Margin is 249.42%, which was down 2453400.0% from 15666.65% recorded in Q2 2023.
  • ADC Therapeutics' 5-year EBIT Margin high stood at 15666.65% for Q2 2023, and its period low was 439583174.87% during Q3 2021.
  • Moreover, its 5-year median value for EBIT Margin was 260.48% (2023), whereas its average is 31399289.46%.
  • Its EBIT Margin has fluctuated over the past 5 years, first tumbled by 2000000000bps in 2021, then soared by 2000000000bps in 2022.
  • Quarter analysis of 5 years shows ADC Therapeutics' EBIT Margin stood at 16095.5% in 2019, then skyrocketed by 100bps to 36.16% in 2020, then plummeted by -1215754084bps to 439583174.87% in 2021, then skyrocketed by 100bps to 15.38% in 2022, then tumbled by -1521bps to 249.42% in 2023.
  • Its EBIT Margin stands at 249.42% for Q3 2023, versus 15666.65% for Q2 2023 and 271.55% for Q1 2023.